National and Kapodistrian University of Athens
Φαρμακοκινητική μελέτη κολιστίνης σε βαρέως πάσχοντες ασθενείς στη μονάδα εντατικής θεραπείας
Abstract
dc:descriptionWe studied the pharmacokinetics of colistin in critically ill patients treated with colistimethate sodium (CMS) for gram negative infections. Colistin penetration into the cerebrospinal fluid (CSF) was studied in five critically ill adult patients receiving colistin methanesulfonate for infections by multiresistant gram-negative bacilli. CSF-to-serum ratios at all sampling times ranged between 0.051 and 0.057. The low level (5%) of penetration suggests inadequate bactericidal colistin concentrations in the CSF. Thereafter, colistin penetration into the cerebrospinal fluid was studied in twelve patients separated into groups with or without CNS infection treated with intravenous (control group and group 1) or combined intravenous (i.v.) and intraventricular administration of CMS (group 2) and the mean CSF-to-serum colistin concentration ratios were found to be increased in patients with ventriculitis (group 1) compared with those without ventriculitis (control group), 0.1 and 0.06, respectively and particularly increased in patients treated with iv plus intraventricular CMS (0.35-0.40). Colistin penetration into alveolar lining fluid (ALF) was studied in two mechanically ventilated multitrauma patients treated with CMS for sepsis. The ALF/ serum colistin concentration ratios of the patients were 1.70 and 7.42. The much higher drug penetration in patient 2 was considered to be probably due to the presence of an active bacterial infection (pneumonia). In another study on two patients with pneumonia the administration of combined i.v. and nebulized CMS resulted in increased mean peak and trough concentrations, 2.23±0.35 μg/ml and 1.08±0.18 μg/ml, respectively, compared to i.v. administration alone 2.67±0.10 μg/ml and 1.51±0.11 μg/ml, respectively. In patients to whom CMS was administered only by nebulizer, using an older model of nebulizer, the concentrations were found to be very low (0.51-0.63 μg/ml). In a further 5 patients with tracheobronchitis the administration of inhaled CMS alone, using a new model nebulizer, achieved higher mean maximum (1.56 μg/ml) and minimum (0.39 μg/ml) concentrations, but these concentrations were much lower than i.v. concentrations, indicating that the administration of CMS by nebulizer the risk of systemic toxicity due to colistin. All patients showed clinical improvement. Sixty critically ill patients with mild renal dysfunction were studied. Maximum and minimum serum concentrations achieved with i.v. CMS doses, administered at the discretion of attending physicians, demonstrated that a lack of CMS dose adjustment according to current recommendations did not result in significantly different maximum (mean±SD) ( 2.94 ± 1.18 vs. 3.56±1.14, p=0.1), (3.07±1.21 vs. 3.71±0.96, p=0.2) and minimum (1.02±0.39 vs. 1.07±0.43, p=0.7), (1.03±0.39 vs. 1.09±0.45, p=0.7) colistin concentrations in these patients compared with patients with normal renal function. In three critically ill patients with impaired but stable renal function, mean steady state colistin concentrations, following i.v. CMS administration, did not reach target concentrations required to achieve a steady-state AUC0-24 of 60 hr*mg/L and pharmacodynamic target AUC0-24 to MIC > 60, in spite of the fact that the CMS daily dose was in 3 out of 5 patients higher than recommended.We studied colistin pharmacokinetics in 3 critically ill patients treated with CMS for Gram negative sepsis and undergoing continuous venovenous hemodiafiltration for acute renal failure. Extracorporeal clearance (43 to 59% of total colistin clearance) resulted in substantial removal of colistin. Only a small fraction of colistin extracorporeal clearance could be attributed to diafiltration. Colistin adsorption by the hemofilter contributed to a large extent to the extracorporeal clearance of colistin. Total colistin clearance was considerably reduced (varying between 3.3 to 4.5 L/h), compared with patients with normal renal function. Although even higher doses of CMS are appropriate in our study, there is need for reduction of doses in critical ill patients with acute renal failure and undergoing CVVHDF.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Fousteri, Marina-Zoe
- Φουστέρη, Μαρίνα-Ζωή
Subjects
dc:subject × 20- Κολιστίνη
- Μεθανοσουλφονική κολιστίνη
- Ψευδομονάδα
- Κοιλιΐτιδα
- Πολυμυξίνες
- Συνεχής φλεβοβλεβική αιμοδιήθηση
- Πνευμονία εξ ανεπνευστήρα
- Μονάδα εντατικής θεραπείας ( ΜΕΘ )
- Colistin
- Methanesulphate colistin
- Pseudomonas
- Ventriculitis
- Polymyxins
- Continuous venovenous diafiltration
- Vendor-associated pneumonia
- Intensive care units (ICU)
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες Υγείας
- Medical and Health Sciences
- Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/28508